Market Executive Summary
Hereditary Angioedema Market was estimated to be worth US$ 1904 million in 2024 and is forecast to a readjusted size of US$ 3093 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hereditary Angioedema, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hereditary Angioedema by region & country, by Type, and by Distribution Channel.
The Hereditary Angioedema market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Angioedema.
Global Hereditary Angioedema Companies Covered
Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Global Hereditary Angioedema Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hereditary Angioedema Market, Segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Global Hereditary Angioedema Market, Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hereditary Angioedema manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Hereditary Angioedema in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Hereditary Angioedema in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Related Reports:
Global Methane Gas Inhibitors Market Size, Share, Growth, Analysis, Trends and Forecast - 2029
Global Checkpoint Inhibitors for Treating Cancer Market Size, Share, Competitive Analysis, Key Players, Growth Drivers, Trends, Opportunities, Revenue Analysis, and Demand Forecast to 2032
Table of Contents
Table of Contents
1 Market Overview
1.1 Hereditary Angioedema Product Introduction
1.2 Global Hereditary Angioedema Market Size Forecast
1.2.1 Global Hereditary Angioedema Sales Value (2020-2031)
1.2.2 Global Hereditary Angioedema Sales Volume (2020-2031)
1.2.3 Global Hereditary Angioedema Sales Price (2020-2031)
1.3 Hereditary Angioedema Market Trends & Drivers
1.3.1 Hereditary Angioedema Industry Trends
1.3.2 Hereditary Angioedema Market Drivers & Opportunity
1.3.3 Hereditary Angioedema Market Challenges
1.3.4 Hereditary Angioedema Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hereditary Angioedema Players Revenue Ranking (2024)
2.2 Global Hereditary Angioedema Revenue by Company (2020-2025)
2.3 Global Hereditary Angioedema Players Sales Volume Ranking (2024)
2.4 Global Hereditary Angioedema Sales Volume by Company Players (2020-2025)
2.5 Global Hereditary Angioedema Average Price by Company (2020-2025)
2.6 Key Manufacturers Hereditary Angioedema Manufacturing Base and Headquarters
2.7 Key Manufacturers Hereditary Angioedema Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Hereditary Angioedema
2.9 Hereditary Angioedema Market Competitive Analysis
2.9.1 Hereditary Angioedema Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Hereditary Angioedema Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Angioedema as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 C1 Esterase Inhibitor
3.1.2 Kallikrein Inhibitor
3.1.3 Selective Bradykinin B2 Receptor Antagonist
3.2 Global Hereditary Angioedema Sales Value by Type
3.2.1 Global Hereditary Angioedema Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Hereditary Angioedema Sales Value, by Type (2020-2031)
3.2.3 Global Hereditary Angioedema Sales Value, by Type (%) (2020-2031)
3.3 Global Hereditary Angioedema Sales Volume by Type
3.3.1 Global Hereditary Angioedema Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Hereditary Angioedema Sales Volume, by Type (2020-2031)
3.3.3 Global Hereditary Angioedema Sales Volume, by Type (%) (2020-2031)
3.4 Global Hereditary Angioedema Average Price by Type (2020-2031)
4 Segmentation by Distribution Channel
4.1 Introduction by Distribution Channel
4.1.1 Retail Pharmacies
4.1.2 Hospital Pharmacies
4.1.3 Online Pharmacies
4.2 Global Hereditary Angioedema Sales Value by Distribution Channel
4.2.1 Global Hereditary Angioedema Sales Value by Distribution Channel (2020 VS 2024 VS 2031)
4.2.2 Global Hereditary Angioedema Sales Value, by Distribution Channel (2020-2031)
4.2.3 Global Hereditary Angioedema Sales Value, by Distribution Channel (%) (2020-2031)
4.3 Global Hereditary Angioedema Sales Volume by Distribution Channel
4.3.1 Global Hereditary Angioedema Sales Volume by Distribution Channel (2020 VS 2024 VS 2031)
4.3.2 Global Hereditary Angioedema Sales Volume, by Distribution Channel (2020-2031)
4.3.3 Global Hereditary Angioedema Sales Volume, by Distribution Channel (%) (2020-2031)
4.4 Global Hereditary Angioedema Average Price by Distribution Channel (2020-2031)
5 Segmentation by Region
5.1 Global Hereditary Angioedema Sales Value by Region
5.1.1 Global Hereditary Angioedema Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Hereditary Angioedema Sales Value by Region (2020-2025)
5.1.3 Global Hereditary Angioedema Sales Value by Region (2026-2031)
5.1.4 Global Hereditary Angioedema Sales Value by Region (%), (2020-2031)
5.2 Global Hereditary Angioedema Sales Volume by Region
5.2.1 Global Hereditary Angioedema Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Hereditary Angioedema Sales Volume by Region (2020-2025)
5.2.3 Global Hereditary Angioedema Sales Volume by Region (2026-2031)
5.2.4 Global Hereditary Angioedema Sales Volume by Region (%), (2020-2031)
5.3 Global Hereditary Angioedema Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Hereditary Angioedema Sales Value, 2020-2031
5.4.2 North America Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Hereditary Angioedema Sales Value, 2020-2031
5.5.2 Europe Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Hereditary Angioedema Sales Value, 2020-2031
5.6.2 Asia Pacific Hereditary Angioedema Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Hereditary Angioedema Sales Value, 2020-2031
5.7.2 South America Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Hereditary Angioedema Sales Value, 2020-2031
5.8.2 Middle East & Africa Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hereditary Angioedema Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Hereditary Angioedema Sales Value
6.2.1 Key Countries/Regions Hereditary Angioedema Sales Value, 2020-2031
6.2.2 Key Countries/Regions Hereditary Angioedema Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Hereditary Angioedema Sales Value, 2020-2031
6.3.2 United States Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.4 Europe
6.4.1 Europe Hereditary Angioedema Sales Value, 2020-2031
6.4.2 Europe Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.5 China
6.5.1 China Hereditary Angioedema Sales Value, 2020-2031
6.5.2 China Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.5.3 China Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.6 Japan
6.6.1 Japan Hereditary Angioedema Sales Value, 2020-2031
6.6.2 Japan Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Hereditary Angioedema Sales Value, 2020-2031
6.7.2 South Korea Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Hereditary Angioedema Sales Value, 2020-2031
6.8.2 Southeast Asia Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
6.9 India
6.9.1 India Hereditary Angioedema Sales Value, 2020-2031
6.9.2 India Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
6.9.3 India Hereditary Angioedema Sales Value by Distribution Channel, 2024 VS 2031
7 Company Profiles
7.1 Pharming Group NV
7.1.1 Pharming Group NV Company Information
7.1.2 Pharming Group NV Introduction and Business Overview
7.1.3 Pharming Group NV Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Pharming Group NV Hereditary Angioedema Product Offerings
7.1.5 Pharming Group NV Recent Development
7.2 Takeda
7.2.1 Takeda Company Information
7.2.2 Takeda Introduction and Business Overview
7.2.3 Takeda Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Takeda Hereditary Angioedema Product Offerings
7.2.5 Takeda Recent Development
7.3 CSL Limited
7.3.1 CSL Limited Company Information
7.3.2 CSL Limited Introduction and Business Overview
7.3.3 CSL Limited Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 CSL Limited Hereditary Angioedema Product Offerings
7.3.5 CSL Limited Recent Development
7.4 iBio Inc.
7.4.1 iBio Inc. Company Information
7.4.2 iBio Inc. Introduction and Business Overview
7.4.3 iBio Inc. Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 iBio Inc. Hereditary Angioedema Product Offerings
7.4.5 iBio Inc. Recent Development
7.5 BioCryst Pharmaceuticals, Inc.
7.5.1 BioCryst Pharmaceuticals, Inc. Company Information
7.5.2 BioCryst Pharmaceuticals, Inc. Introduction and Business Overview
7.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product Offerings
7.5.5 BioCryst Pharmaceuticals, Inc. Recent Development
7.6 Ionis Pharmaceuticals, Inc.
7.6.1 Ionis Pharmaceuticals, Inc. Company Information
7.6.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview
7.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product Offerings
7.6.5 Ionis Pharmaceuticals, Inc. Recent Development
8 Industry Chain Analysis
8.1 Hereditary Angioedema Industrial Chain
8.2 Hereditary Angioedema Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hereditary Angioedema Sales Model
8.5.2 Sales Channel
8.5.3 Hereditary Angioedema Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Figures
Table of Figures
List of Tables
Table 1. Hereditary Angioedema Market Trends
Table 2. Hereditary Angioedema Market Drivers & Opportunity
Table 3. Hereditary Angioedema Market Challenges
Table 4. Hereditary Angioedema Market Restraints
Table 5. Global Hereditary Angioedema Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Hereditary Angioedema Revenue Market Share by Company (2020-2025)
Table 7. Global Hereditary Angioedema Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global Hereditary Angioedema Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Hereditary Angioedema Price by Company (2020-2025) & (USD/Unit)
Table 10. Key Manufacturers Hereditary Angioedema Manufacturing Base and Headquarters
Table 11. Key Manufacturers Hereditary Angioedema Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Hereditary Angioedema
Table 13. Global Hereditary Angioedema Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Angioedema as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Hereditary Angioedema Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Hereditary Angioedema Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Hereditary Angioedema Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Hereditary Angioedema Sales Market Share in Value by Type (2020-2025)
Table 20. Global Hereditary Angioedema Sales Market Share in Value by Type (2026-2031)
Table 21. Global Hereditary Angioedema Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Hereditary Angioedema Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global Hereditary Angioedema Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global Hereditary Angioedema Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Hereditary Angioedema Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Hereditary Angioedema Price by Type (2020-2025) & (USD/Unit)
Table 27. Global Hereditary Angioedema Price by Type (2026-2031) & (USD/Unit)
Table 28. Global Hereditary Angioedema Sales Value by Distribution Channel: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Hereditary Angioedema Sales Value by Distribution Channel (2020-2025) & (US$ Million)
Table 30. Global Hereditary Angioedema Sales Value by Distribution Channel (2026-2031) & (US$ Million)
Table 31. Global Hereditary Angioedema Sales Market Share in Value by Distribution Channel (2020-2025)
Table 32. Global Hereditary Angioedema Sales Market Share in Value by Distribution Channel (2026-2031)
Table 33. Global Hereditary Angioedema Sales Volume by Distribution Channel: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global Hereditary Angioedema Sales Volume by Distribution Channel (2020-2025) & (K Units)
Table 35. Global Hereditary Angioedema Sales Volume by Distribution Channel (2026-2031) & (K Units)
Table 36. Global Hereditary Angioedema Sales Market Share in Volume by Distribution Channel (2020-2025)
Table 37. Global Hereditary Angioedema Sales Market Share in Volume by Distribution Channel (2026-2031)
Table 38. Global Hereditary Angioedema Price by Distribution Channel (2020-2025) & (USD/Unit)
Table 39. Global Hereditary Angioedema Price by Distribution Channel (2026-2031) & (USD/Unit)
Table 40. Global Hereditary Angioedema Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Hereditary Angioedema Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Hereditary Angioedema Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Hereditary Angioedema Sales Value by Region (2020-2025) & (%)
Table 44. Global Hereditary Angioedema Sales Value by Region (2026-2031) & (%)
Table 45. Global Hereditary Angioedema Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global Hereditary Angioedema Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global Hereditary Angioedema Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global Hereditary Angioedema Sales Volume by Region (2020-2025) & (%)
Table 49. Global Hereditary Angioedema Sales Volume by Region (2026-2031) & (%)
Table 50. Global Hereditary Angioedema Average Price by Region (2020-2025) & (USD/Unit)
Table 51. Global Hereditary Angioedema Average Price by Region (2026-2031) & (USD/Unit)
Table 52. Key Countries/Regions Hereditary Angioedema Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Hereditary Angioedema Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Hereditary Angioedema Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Hereditary Angioedema Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions Hereditary Angioedema Sales Volume, (2026-2031) & (K Units)
Table 57. Pharming Group NV Company Information
Table 58. Pharming Group NV Introduction and Business Overview
Table 59. Pharming Group NV Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Pharming Group NV Hereditary Angioedema Product Offerings
Table 61. Pharming Group NV Recent Development
Table 62. Takeda Company Information
Table 63. Takeda Introduction and Business Overview
Table 64. Takeda Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Takeda Hereditary Angioedema Product Offerings
Table 66. Takeda Recent Development
Table 67. CSL Limited Company Information
Table 68. CSL Limited Introduction and Business Overview
Table 69. CSL Limited Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. CSL Limited Hereditary Angioedema Product Offerings
Table 71. CSL Limited Recent Development
Table 72. iBio Inc. Company Information
Table 73. iBio Inc. Introduction and Business Overview
Table 74. iBio Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. iBio Inc. Hereditary Angioedema Product Offerings
Table 76. iBio Inc. Recent Development
Table 77. BioCryst Pharmaceuticals, Inc. Company Information
Table 78. BioCryst Pharmaceuticals, Inc. Introduction and Business Overview
Table 79. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product Offerings
Table 81. BioCryst Pharmaceuticals, Inc. Recent Development
Table 82. Ionis Pharmaceuticals, Inc. Company Information
Table 83. Ionis Pharmaceuticals, Inc. Introduction and Business Overview
Table 84. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product Offerings
Table 86. Ionis Pharmaceuticals, Inc. Recent Development
Table 87. Key Raw Materials Lists
Table 88. Raw Materials Key Suppliers Lists
Table 89. Hereditary Angioedema Downstream Customers
Table 90. Hereditary Angioedema Distributors List
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Hereditary Angioedema Product Picture
Figure 2. Global Hereditary Angioedema Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Hereditary Angioedema Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Hereditary Angioedema Sales Volume (2020-2031) & (K Units)
Figure 5. Global Hereditary Angioedema Sales Price (2020-2031) & (USD/Unit)
Figure 6. Hereditary Angioedema Report Years Considered
Figure 7. Global Hereditary Angioedema Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Hereditary Angioedema Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Hereditary Angioedema Revenue in 2024
Figure 10. Hereditary Angioedema Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. C1 Esterase Inhibitor Picture
Figure 12. Kallikrein Inhibitor Picture
Figure 13. Selective Bradykinin B2 Receptor Antagonist Picture
Figure 14. Global Hereditary Angioedema Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Hereditary Angioedema Sales Value Market Share by Type, 2024 & 2031
Figure 16. Global Hereditary Angioedema Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 17. Global Hereditary Angioedema Sales Volume Market Share by Type, 2024 & 2031
Figure 18. Global Hereditary Angioedema Price by Type (2020-2031) & (USD/Unit)
Figure 19. Product Picture of Retail Pharmacies
Figure 20. Product Picture of Hospital Pharmacies
Figure 21. Product Picture of Online Pharmacies
Figure 22. Global Hereditary Angioedema Sales Value by Distribution Channel (2020 VS 2024 VS 2031) & (US$ Million)
Figure 23. Global Hereditary Angioedema Sales Value Market Share by Distribution Channel, 2024 & 2031
Figure 24. Global Hereditary Angioedema Sales Volume by Distribution Channel (2020 VS 2024 VS 2031) & (K Units)
Figure 25. Global Hereditary Angioedema Sales Volume Market Share by Distribution Channel, 2024 & 2031
Figure 26. Global Hereditary Angioedema Price by Distribution Channel (2020-2031) & (USD/Unit)
Figure 27. North America Hereditary Angioedema Sales Value (2020-2031) & (US$ Million)
Figure 28. North America Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
Figure 29. Europe Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 30. Europe Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
Figure 31. Asia Pacific Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Hereditary Angioedema Sales Value by Region (%), 2024 VS 2031
Figure 33. South America Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 34. South America Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
Figure 35. Middle East & Africa Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 36. Middle East & Africa Hereditary Angioedema Sales Value by Country (%), 2024 VS 2031
Figure 37. Key Countries/Regions Hereditary Angioedema Sales Value (%), (2020-2031)
Figure 38. Key Countries/Regions Hereditary Angioedema Sales Volume (%), (2020-2031)
Figure 39. United States Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 40. United States Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 41. United States Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 42. Europe Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 43. Europe Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 44. Europe Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 45. China Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 46. China Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 47. China Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 48. Japan Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 49. Japan Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 50. Japan Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 51. South Korea Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 52. South Korea Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 53. South Korea Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 54. Southeast Asia Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 55. Southeast Asia Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 56. Southeast Asia Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 57. India Hereditary Angioedema Sales Value, (2020-2031) & (US$ Million)
Figure 58. India Hereditary Angioedema Sales Value by Type (%), 2024 VS 2031
Figure 59. India Hereditary Angioedema Sales Value by Distribution Channel (%), 2024 VS 2031
Figure 60. Hereditary Angioedema Industrial Chain
Figure 61. Hereditary Angioedema Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
This report focuses on:
► Intelligent insights to take informed business decisions.
► Qualitative and quantitative analysis of the market.
► Market size and forecasts from 2024 to 2030.
► Opportunities for expansion and in-depth market analysis.
► Segmentation and regional revenue forecasts.
► Analysis of the market share and competitive landscape.
► Strategic recommendations for future growth.
You'll also receive:
► A comprehensive market research report in PDF or PPT formats.
► Access to our analysts to learn more about the report and get answers to your specific business questions.
► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.
Contact us today to learn more and get sample report.
Our Research Reports Look Like This
